Statin pre-treatment is associated with lower platelet activity and favorable outcome in patients with acute non-cardio-embolic ischemic stroke

Table 3 Prognostic factors of patients with acute ischemic stroke

	Good outcome (n= 133)	Poor outcome (n= 39)	Pvalue
Age (year)
Sex (female) (%)	32.3	46.2	0.11
Hypertension (%)	77.4	84.6	0.33
Diabetes mellitus (%)	38.3	48.7	0.25
Hyperlipidemia (%)	50.4	38.5	0.19
Coronary artery disease (%)	1.5	12.8	0.002
Intra-cranial atherosclerosis (%)	23.3	30.8	0.34
Stroke sub-type
Small vessel disease (%)	57.1	48.7	0.24
Large vessel disease (%)	39.1	51.3
Statin therapy groups
Pre-existing statin use (%)	29.3	10.3	0.016
Median NIHSS (IQR) scores on admission	3 (1-5)	4 (3-8)	0.009
Laboratory data on admission
White blood cells (X10³/ml)	7.5 ± 0.2	7.6 ± 0.4	0.69
Red blood cells (X10⁶/ml)	4.6 ± 0.1	4.6 ± 0.1	0.73
Platelet counts (X10⁴/ml)	21.2 ± 0.6	19.5 ± 0.7	0.06
Total cholesterol (mg/dl)	183.0 ± 4.2	187.8 ± 8.5	0.61
LDL-cholesterol (mg/dl)	113.7 ± 3.7	114.3 ± 6.7	0.93
Triglyceride (mg/dl)	143.1 ± 7.8	147.2 ± 8.5	0.82
HbA1c (%)	7.0 ± 0.2	7.4 ± 0.4	0.33
Systolic BP (mmHg)	143.4 ± 1.8	140.6 ± 3.5	0.46
Diastolic BP (mmHg)	83.8 ± 1.1	82.8 ± 2.1	0.67
Platelet markers on admission
CD62P (%)†	3.45 ± 0.38	5.39 ± 0.89	0.024
CD63 (%)†	1.41 ± 0.12	1.99 ± 0.31	0.035

Good outcome, three-month mRS (0 to 2); poor outcome, three-month modified Rankin Scale (3 to 6).
BP, blood pressure; HbA1c, hemoglobin A1c; IQR, inter-quartile range; LDL, low density lipoprotein; NIHSS, National Institutes of Health Stroke Scale;
† The data was expressed as primitive data, however, the p value was obtained from logarithmically transformed of primitive data to improved normality.

ISSN: 1364-8535